317 articles
Somapacitan
Somapacitan (Sogroya) is Novo Nordisk's once-weekly, reversible albumin-binding human growth hormone analog for growth hormone deficiency in adults and children 2.5 years and older, FDA-approved August 28, 2020.
Somatostatin analog therapy
Somatostatin analog therapy uses long-lasting synthetic versions of the hormone somatostatin, such as octreotide and lanreotide, to control hormonal symptoms and slow tumor growth in acromegaly and neuroendocrine tumors.
Sorbinil
Sorbinil, a Pfizer aldose reductase inhibitor (hydantoin class) for diabetic complications; first ARI in clinical trials, failed efficacy in the Sorbinil Retinopathy Trial, withdrawn for hypersensitivity.
Sotagliflozin
Sotagliflozin, sold as INPEFA, is an oral drug inhibiting both SGLT2 and SGLT1, approved in the US in 2023 to lower cardiovascular death and heart failure hospitalization risk in adults.
SRSD216
SRSD216 is an investigational Lp(a)-lowering siRNA from Sirius Therapeutics targeting LPA mRNA; Phase 1 single doses cut Lp(a) up to 94.7% with effects lasting over seven months.
Statin
Statin: HMG-CoA reductase inhibitor lowering LDL cholesterol; first statin mevastatin from Penicillium citrinum (Endo, 1970s), lovastatin FDA-approved 1987; first-line therapy for ASCVD prevention per 2026 ACC/AHA dyslipidemia guideline.
Sudi insulin
Sudi insulin (舒地胰岛素, insulin sudelidec, INS068, brand Rihengying) is Hengrui's long-acting basal insulin analog for adult type 2 diabetes; NMPA-approved 28 July 2026 as China's first independently developed long-acting insulin analog, non-inferior to glargine with lower nocturnal hypoglycemia.
Survodutide
Survodutide (BI 456906) is an investigational once-weekly injectable drug by Boehringer Ingelheim that acts on glucagon and GLP-1 receptors for obesity, type 2 diabetes, and MASH.
SYH2068
SYH2068 is CSPC Pharmaceutical Group's GalNAc-conjugated double-stranded siRNA injection targeting lipoprotein(a) for hyperlipoproteinemia(a); NMPA-approved April 2025, in Phase 1/2 trials in China (NCT07640217).
SYH2082
SYH2082 is CSPC Pharmaceutical's long-acting GLP1R/GIPR dual-agonist peptide for once-monthly injectable obesity treatment using the LiquidGel platform; licensed to AstraZeneca in January 2026 for up to $18.5 billion, now in Phase I.
SYH2086, oral small-molecule GLP-1 receptor agonist
SYH2086 (MGL-2086) is CSPC Pharmaceutical Group's preclinical oral small-molecule GLP-1 receptor agonist, an orforglipron derivative licensed globally to Madrigal Pharmaceuticals in July 2025 for up to US$2.075 billion for MASH combination therapy.
Taspoglutide
Taspoglutide (BIM-51077, R-1583), a once-weekly GLP-1 receptor agonist from Ipsen licensed to Roche for type 2 diabetes; effective in T-emerge phase 3 trials but abandoned in 2010 over GI intolerance, antibodies, and anaphylaxis.
Teneligliptin
Teneligliptin (Tenelia, MP-513) is an oral DPP-4 inhibitor by Mitsubishi Tanabe Pharma for type 2 diabetes, first approved in Japan in 2012, dosed 20-40 mg once daily, with no dose adjustment needed in renal or hepatic impairment.
Tesaglitazar
Tesaglitazar (Galida, AZ-242), an AstraZeneca dual PPARα/γ agonist for type 2 diabetes, lowered glucose and triglycerides in trials but was discontinued in May 2006 over creatinine and GFR effects.
Tesamorelin
Tesamorelin (Egrifta, TH9507) is a synthetic 44-amino-acid GHRH analogue, FDA approved in 2010 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy; it lowers visceral fat about 15-20% and raises IGF-1, with edema, arthralgia, and glucose intolerance as risks.
Testosterone replacement therapy
Testosterone replacement therapy (TRT) is the medical administration of testosterone, usually as a gel, injection, patch, or pellet, to restore normal hormone levels in men with hypogonadism.
TG103
TG103 (依达格鲁肽α) is a once-weekly GLP-1/Fc fusion protein injection by CSPC Baike for type 2 diabetes and obesity; phase 3 trials completed in China, CDE filing accepted.
Thyrotropin alfa
Thyrotropin alfa (Thyrogen, rhTSH) is a recombinant human thyroid-stimulating hormone injected intramuscularly to detect and ablate thyroid remnants after thyroidectomy for well-differentiated thyroid cancer.
Tigulixostat
Tigulixostat, also known by the development code LC350189, is a once-daily, selective xanthine oxidase inhibitor from LG Chem for lowering serum urate in gout, now in Phase 3 trials.
Tiludronic acid
Tiludronic acid (tiludronate, SR 41319, Skelid, Tildren) is a first-generation non-nitrogen bisphosphonate inhibiting osteoclasts, FDA-approved in 1997 for Paget's disease and used intravenously for navicular syndrome in horses.
Tiratricol
Tiratricol (Triac, Emcitate), a T3 thyroid hormone analogue that enters cells without the MCT8 transporter; first approved treatment for peripheral thyrotoxicosis in MCT8 deficiency (Allan-Herndon-Dudley syndrome), EU 2025, US 2026.
Tisopurine
Tisopurine (thiopurinol, Exuracid, NSC-1392), C5H4N4S, CAS 5334-23-6, ATC M04AA02, is the 4-thio analog of allopurinol, an approved antigout drug that lowers uric acid by interfering with early urate synthesis rather than xanthine oxidase inhibition.
Tofogliflozin anhydrous
Tofogliflozin anhydrous is the anhydrous form of tofogliflozin, a highly selective SGLT2 inhibitor approved in Japan in 2014 for adults with type 2 diabetes, sold as DEBERZA and Apleway.
Tolazamide
Tolazamide (Tolinase) is a first-generation sulfonylurea oral drug for type 2 diabetes, FDA approved July 1966, about 5-6 times as potent as tolbutamide, no longer available in the United States.
Tolrestat
Tolrestat (Alredase, AY-27,773), an aldose reductase inhibitor for diabetic neuropathy, approved 1988, showed modest nerve-function benefit in trials, and was withdrawn worldwide in 1996 after fatal hepatic necrosis.
TRC4186
TRC4186 (also written TRC-4186) is a pyridinium advanced glycation end-product (AGE) cross-link breaker from Torrent Pharmaceuticals, India, tested for diabetic cardiomyopathy and heart failure; its Phase II trial ended early on safety grounds.
Trelagliptin
Trelagliptin (SYR-472, Zafatek) is a once-weekly oral DPP-4 inhibitor for type 2 diabetes, approved in Japan in March 2015 as the first once-weekly oral antidiabetic; 100 mg weekly, non-inferior to daily alogliptin.
Tricaprilin
Tricaprilin (AC-1202, CER-0001, glyceryl tricaprylate) is an 8-carbon medium-chain triglyceride ketogenic agent studied for mild to moderate Alzheimer's disease, marketed as Axona, with benefit mainly in APOE4-negative patients.
Triheptanoin
Triheptanoin, sold as Dojolvi and developed by Ultragenyx as UX007, is a synthetic odd-chain triglyceride approved in 2020 to supply calories and fatty acids in long-chain fatty acid oxidation disorders.
Trimegestone
Trimegestone (RU-27987, 21-hydroxypromegestone) is a synthetic 19-norpregnane progestin used with estradiol in menopausal hormone therapy; potent, progesterone-receptor selective, dosed 0.0625-0.5 mg, also studied in a contraceptive vaginal ring.